Medication info

Janusita Tablet 50 mg (Sitagliptin Phosphate)

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate›62.04mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Bright beige, bilaterally convex, round film-coated tablet
Packaging
30 tablets/box [10 tablets/PTPX3 units]
Approval status
Expired

MFDS item code 201503269 · Approved 2015.05.28

This product's status changed to Expired on 2025.05.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For monotherapy or combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment As dosage adjustment according to renal function is necessary, assessment of renal function is recommended before and periodically after administration of this medicine. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used to aid in blood sugar control for patients with type 2 diabetes. Initially, it can be administered alone in combination with dietary and exercise therapy. If sufficient blood sugar control is difficult with monotherapy, it can be used in conjunction with metformin. Additionally, it can be administered in combination with other antidiabetic medications such as sulfonylureas, metformin, thiazolidinediones, and insulin. When blood sugar control is challenging with multiple drug combination therapy, this medication can be added to improve blood sugar control. This medication enhances blood sugar management in patients with type 2 diabetes at various treatment stages.

How to take

Adult dose

For monotherapy or combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment As dosage adjustment according to renal function is necessary, assessment of renal function is recommended before and periodically after administration of this medicine. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Precautions

This medication may cause severe hypersensitivity reactions, so if symptoms such as skin rash, angioedema, or difficulty breathing occur within 3 months after administration, usage should be immediately discontinued and medical attention sought. Acute pancreatitis may occur during the use of this drug; therefore, if symptoms such as abdominal pain, vomiting, or persistent abdominal discomfort appear, medical personnel should be informed immediately. This drug should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients with hypersensitivity to this drug or its components should not take it. Patients with decreased kidney function may need dosage adjustment; it is important to perform kidney function tests before administration. Hypoglycemia symptoms may occur while taking this drug, so blood sugar should be monitored regularly, especially when taken with insulin or sulfonylureas. Severe joint pain or blistering skin conditions may arise; consult a physician immediately if such symptoms occur. It is safer for pregnant or breastfeeding women not to take this drug. Elderly patients may have reduced kidney function, requiring dosage adjustments and kidney function testing. In case of overdose, immediate hospital visit for appropriate treatment is necessary; this drug can be partially removed by hemodialysis. Due to the potential for drug interactions, inform your doctor or pharmacist if you are currently taking any medications.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative dermatitis
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infection
  • nasopharyngitis
  • headache
Show 32 more
  • diarrhea
  • abdominal pain
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • arthritis with severity and disability
  • blistering dermatitis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • increased low-density lipoprotein
  • hyperglycemia
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight closed container, kept at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the drug.

Appearance and packaging

Appearance

Bright beige, bilaterally convex, round film-coated tablet

Package unit

30 tablets/box [10 tablets/PTPX3 units]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.